1,4-Difluoro-2-(3-methylbutan-2-yl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,4-Difluoro-2-(3-methylbutan-2-yl)benzene
• 英文别名: 1,4-difluoro-2-(3-methylbutan-2-yl)benzene
• 化学式: C₁₁H₁₄F₂
• 分子量: 184.23
• InChiKey: IEBYQMZUNRVING-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMT inhibiting methods and compositions
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US10934283B2

  公开（公告）日：2021-03-02

  Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.

  本文提供了抑制 COMT 酶的化合物和包含这些化合物的药物组合物。本文还提供了使用本文所述化合物和药物组合物治疗各种精神和神经疾病的方法。
• TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
  申请人：Lieber Institute Inc. DBA Lieber Institute For Brain Development

  公开号：EP3380471B1

  公开（公告）日：2021-09-08
• THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20170217923A1

  公开（公告）日：2017-08-03

  Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.
• COMT Inhibiting Methods and Compositions
  申请人：LIEBER INSTITUTE, INC.

  公开号：US20210139479A1

  公开（公告）日：2021-05-13

  This invention relates to compounds, pharmaceutical compositions and their use for treating neuropsychiatric and neurodegenerative disorders. In particular, the invention relates to inhibitors of catechol-O-methyltransferase and their use as therapeutics for central nervous system disease.